Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
AmphiStar BV secures €6m to expand production
The infusion of €6m in new capital from ECBF, Qbic III and FFTF will empower AmphiStar to kickstart commercial biosurfactant production in...
Spexis sells antibiotics programme to Basilea
Spexis AG (Alschwil) has entered into an asset purchase agreement with Basilea Pharmaceutica Ltd. Under the agreement Basilea will acquire a...
Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN
Finnish Biovian Oy and Pamplona-based 3P Biopharmaceuticals Srl have joined forces to build a pan-European Contract Development and Manufacturing...
EU parliament backs deregulation of New Genome Techniques
With the MEPs' approval of the amendments to the European Commission's draft legislation, the way is now clear for a regulation that distinguishes...
AZmed closes €15m Series A financing
AZmed said it will use the €15m to boost marketing of its proprietary artificial intelligence (AI) platform Rayvolve worldwide particularly in...
Genmab broadens ADC pipeline with $1.8bn acquisition of ProfoundBio
The acquisition will give Genmab access to ProfoundBio's portfolio of antibody-drug conjugates (ADCs), three of which are in clinical trials. The...